Oxaliplatin: available data in non-colorectal gastrointestinal malignancies

Bécouarn, Y.; Agostini, Cécile; Trufflandier, Nathalie; Boulanger, Vincent

doi:10.1016/s1040-8428(01)00169-x

Cited by 41 publications

(25 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(7,8) and potentially in colorectal gastrointestinal tumors (9). Several phase II clinical trials have demonstrated an overall response rate ranging from 42% to 49% for treating advanced gastric cancer with oxaliplatin combined with 5-FU and folic acid (7,10,11).…”

Section: Resultsmentioning

confidence: 99%

Outcomes of Modified FOLFOX-6 as First Line Treatment in Patients with Advanced Gastric Cancer in a Single Institution; Retrospective Analysis

et al. 2010

View full text Add to dashboard Cite

I n t r o d u c t i o nIncreasing early diagnosis of gastric cancer has improved the survival rate. However, the prognosis for recurrent or unresectable gastric cancer remains poor. Various chemotherapy regimens have been developed for advanced gastric cancer patients based on the understanding that chemotherapy can increase the length and quality of life (1). However, only 10% of patients treated with chemotherapy survive for longer than 2 years (2).The older-generation 5-fluorouracil (FU) and cisplatin-based combination regimens have proven unsatisfactory, with a response rate of only 11% to 20%, and a median survival time ranging between 6 and 8 months (3,4). In recent randomized trials of a new-generation regimen with oral 5-FU and irinotecan, the overall response rate ranged from 25% to 41% (5,6). However, there remains no standard chemotherapeutic regimen for advanced gastric cancer due to concerns of chemotherapy-induced toxicity and inconsistent treatment responses.Oxaliplatin PurposeTreatment options for patients with advanced gastric cancer remain limited. Few studies have investigated the efficacy and tolerability of the combination regimen of oxaliplatin and 5-fluorouracil with leucovorin for patients with advanced gastric cancer. The goal of this study was to examine the efficacy and toxicity of a modified FOLFOX-6 (mFOLFOX-6) regimen as a first-line chemotherapy regimen for patients with advanced gastric cancer. From March, 2006, to December, 2007 patients with advanced gastric cancer received 100 mg/m 2 oxaliplatin and 100 mg/m 2 leucovorin on the first day of treatment, followed by 2,400 mg/m 2 of 5-fluorouracil on the first and second days of treatment every 2 weeks as a first-line treatment. Materials and Methods ResultsThe median age of the enrolled patients was 62 years (range; 30�75). Out of 82 patients, 34 cases (41.5%) were recurrent cases after curative resection, and the other 48 cases were unresectable or non-curative resectable cases. Their response was evaluated every 6 weeks. The overall response rate was 40.2%, with 2 (2.4%) complete response and 31 (37.8%) partial responses. The median time to progression (TTP) and overall survival (OS) time were 6.0 months (95% confidence interval [CI]: 4.69�7.31) and 13.0 months (7.99�18.0), respectively. The grade 3�4 hematologic toxicities observed included neutropenia (34.1%), thrombocytopenia (7.3%), and anemia (1.2%). The gastrointestinal toxicities observed included grade 3�4 nausea (9.8%) and vomiting (7.3%). Six patients (7.3%) experienced grade 3 neuropathy. No treatment-related deaths were recorded. ConclusionThe modified FOLFOX-6 regimen is effective and well tolerated as a first-line chemotherapy regimen for patients with advanced gastric cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

Outcomes of Modified FOLFOX-6 as First Line Treatment in Patients with Advanced Gastric Cancer in a Single Institution; Retrospective Analysis

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Oxaliplatin has shown efficacy against many tumor cell lines, including some that are resistant to cisplatin and carboplatin (6). In addition, it has demonstrated additive or synergistic activity, and especially when combined with 5-fluorouracil (FU) and even for treating 5-FUresistant cell lines (7,8) …”

Section: Introductionmentioning

confidence: 99%

Oxaliplatin, 5-fluorouracil and Leucovorin (FOLFOX-4) Combination Chemotherapy as a Salvage Treatment in Advanced Gastric Cancer

et al. 2010

View full text Add to dashboard Cite

“…Oxaliplatin is a third generation platinum derivative that differs from cisplatin and carboplatin in that it contains a cyclic, bulky group that may confer greater resistance to DNA repair and efficiently prevent DNA replication once oxaliplatin-DNA adducts have been formed [25]. Oxaliplatin demonstrates mild toxicity and good clinical management [2,6]. CPT11 is a derivate of camptothecin and acts by interfering with the activity of DNA topoisomerase I, which cuts and relegates single-strand DNA.…”

Section: Introductionmentioning

confidence: 99%

Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation

et al. 2006

View full text Add to dashboard Cite

Pancreatic cancer is an aggressive neoplasia, and standard chemotherapies are by and large ineffective. The purpose of this work was to get a comprehensive preclinical study on the ability of anticancer drug combinations that best inhibit growth of pancreatic adenocarcinoma cells. We evaluated the in vitro growth inhibition of ten pancreatic cancer cell lines to gemcitabine and 5-fluorouracil, newer generation cytotoxic agents (oxaliplatin, irinotecan), targeted therapy (gefitinib) and a histone deacetylase (HDAC) inhibitor (trichostatin A). Cells were treated with the single drug alone and all pairwise drug association. Our results demonstrate that TSA can effectively increase the drug sensitivity of all the cell lines studied. The association of TSA and irinotecan determines an increase in growth inhibition on the highest percentage of cell lines (80%). Our findings may represent an experimental basis for potential clinical application of HDAC inhibitors, in particular in association with drugs used in cancer clinical treatment, supporting the idea that HDAC inhibitors could act as sensitizers for chemotherapy.

show abstract

Oxaliplatin: available data in non-colorectal gastrointestinal malignancies

Cited by 41 publications

References 15 publications

Outcomes of Modified FOLFOX-6 as First Line Treatment in Patients with Advanced Gastric Cancer in a Single Institution; Retrospective Analysis

Outcomes of Modified FOLFOX-6 as First Line Treatment in Patients with Advanced Gastric Cancer in a Single Institution; Retrospective Analysis

Oxaliplatin, 5-fluorouracil and Leucovorin (FOLFOX-4) Combination Chemotherapy as a Salvage Treatment in Advanced Gastric Cancer

Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation

Contact Info

Product

Resources

About